Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
The ruling brings closure to a nearly decade-long investigation into hospital operations and healthcare delivery practices
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
BMS is moving beyond conversational AI into what it describes as “agentic” systems
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Solutions designed to help clinicians reduce administrative burden, improve diagnostic accuracy, and spend more time with patients
Subscribe To Our Newsletter & Stay Updated
